膀胱がん市場：2033年までの疫学予測

膀胱がんは、膀胱に発生するがんの一種であり、多くの場合、膀胱の内側を覆う尿路上皮細胞に発生します。尿路上皮がんは膀胱がん全体の90％以上を占めています。世界的に見て、膀胱がんは9番目に多いがん種です。診断は主に侵襲的な処置である膀胱鏡検査に依存するため、この疾患の診断は課題も多く、費用もかかります。ほとんどの膀胱がんは、治療可能な早期段階で診断されるが、再発率はかなり高いものとなっています。最も一般的な症状は、血尿、排尿困難、頻尿、背部痛、骨盤痛などです。

膀胱がんは、筋非浸潤性膀胱がん（NMIBC）と筋浸潤性膀胱がん（MIBC）に大別されます。MIBCはさらに局所進行膀胱がんと転移性膀胱がんに分類されます。NMIBCは、欧州泌尿器科学会（EAU）2021によって、低リスク、中間リスク、高リスク、超高リスクに分類されています。FGFR 2遺伝子、FGFR 3遺伝子、HER 2遺伝子の遺伝子変異は、膀胱がん発症リスクの上昇と関連しています。これらの遺伝子変異に基づいて、医師は患者の治療と予後を決定します。

主要8ヶ国では、膀胱がんの診断された罹患数は2023年の279,419例から2033年には341,879例に増加し、年間成長率（AGR）は2.24％になると予想されています。2033年には、米国が主要8ヶ国Mで最も多く98,184例の膀胱がんと診断され、一方フランスは最も少なく18,425例となります。主要8ヶ国では、5年間に診断される膀胱がんの有病者数は2023年の987,497例から2033年には1,202,635例に増加すると予測され、AGRは2.18%です。

当レポートでは、主要8ヶ国市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本、カナダ）における膀胱がんの危険因子、併存疾患、世界および過去の疫学動向について概説し、クローン病の診断済み発症例と診断済み有病率に関する10年間の疫学予測などをまとめています。

目次

第1章 膀胱がん：エグゼクティブサマリー

第2章 疫学

• 病気の背景
• リスク要因と併存疾患
• 世界的および歴史的動向
• 主要8ヶ国予測調査手法
• 膀胱がんの疫学予測（2023年～2033年）
• 議論

第3章 付録

• 文献
• 著者について
• お問い合わせ

List of Tables

• Table 1: Summary of newly added data types
• Table 2: Summary of updated data types
• Table 3: Risk factors and comorbidities for bladder cancer
• Table 4: 8MM, diagnosed incident cases of bladder cancer by stage at diagnosis using the AJCC TNM staging, N, both sexes, ages >=18 years, 2023
• Table 5: 8MM, diagnosed incident cases of bladder cancer by tumor "T" stage at diagnosis, N, both sexes, ages >=18 years, 2023
• Table 6: 8MM, diagnosed incident cases of bladder cancer by mutations and biomarkers, N, both sexes, ages >=18 years, 2023
• Table 7: 8MM, five-year diagnosed prevalent cases of bladder cancer by tumor stage, N, both sexes, ages >=18 years, 2023

List of Figures

• Figure 1: 8MM, diagnosed incident cases of bladder cancer, both sexes, N, ages >=18 years, 2023 and 2033
• Figure 2: 8MM, five-year diagnosed prevalent cases of bladder cancer, both sexes, N, ages >=18 years, 2023 and 2033
• Figure 3: 8MM, diagnosed incidence of bladder cancer, cases per 100,000 population, men, ages >=18 years, 2013-33
• Figure 4: 8MM, diagnosed incidence of bladder cancer, cases per 100,000 population, women, ages >=18 years, 2013-33
• Figure 5: 8MM, sources used and not used to forecast the diagnosed incidence of bladder cancer
• Figure 6: 8MM, sources used to forecast the diagnosed incident cases by stage at diagnosis using the AJCC TNM staging
• Figure 7: 8MM, sources used to forecast the diagnosed incident cases by tumor "T" stage at diagnosis
• Figure 8: 8MM, sources used to forecast the diagnosed incident cases of stage Ta bladder cancer by grade
• Figure 9: 8MM, sources used to forecast the diagnosed incident cases of bladder cancer and five-year diagnosed prevalent cases of bladder cancer by broad classification
• Figure 10: 8MM, sources used to forecast the diagnosed incident cases of NMIBC by risk group
• Figure 11: 8MM, sources used to forecast the diagnosed incident cases of bladder cancer by mutations and biomarkers
• Figure 12: 8MM, sources used to forecast the five-year diagnosed prevalent cases of bladder cancer
• Figure 13: 8MM, sources used to forecast the five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence
• Figure 14: 8MM, sources used to forecast the five-year diagnosed prevalent cases of bladder cancer by treatment
• Figure 15: 8MM, diagnosed incident cases of bladder cancer, N, both sexes, ages >=18 years, 2023
• Figure 16: 8MM, diagnosed incident cases of bladder cancer by age, N, both sexes, 2023
• Figure 17: 8MM, diagnosed incident cases of bladder cancer by sex, N, ages >=18 years, 2023
• Figure 18: 8MM, diagnosed incident cases of stage Ta bladder cancer by grade, N, both sexes, ages >=18 years, 2023
• Figure 19: 8MM, diagnosed incident cases of bladder cancer by broad classification, N, both sexes, ages >=18 years, 2023
• Figure 20: 8MM, diagnosed incident cases of NMIBC by risk group, N, both sexes, ages >=18 years, 2023
• Figure 21: 8MM, five-year diagnosed prevalent cases of bladder cancer, N, both sexes, ages >=18 years, 2023
• Figure 22: 8MM, five-year diagnosed prevalent cases of bladder cancer by broad classification, N, both sexes, ages >=18 years, 2023
• Figure 23: 8MM, five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence, N, both sexes, ages >=18 years, 2023
• Figure 24: 8MM, five-year diagnosed prevalent cases of bladder cancer by treatment, N, both sexes, ages >=18 years, 2023

Bladder cancer (International Classification of Diseases, 10th Revision [ICD-10] codes C67 [0-9]) is a type of cancer that begins in the urinary bladder, most often in the urothelial cells lining the inside of urinary bladder. Urothelial carcinomas make up more than 90% of all bladder cancers (American Cancer Society, 2024c). Globally, bladder cancer is the ninth most common cancer type. Diagnosis of the disease is both challenging and expensive since diagnosis relies mainly on cystoscopy, which is an invasive procedure (International Agency for Research on Cancer, 2024a). Although most bladder cancers are diagnosed at an early stage when they are highly treatable, the relapse and recurrence rates are quite high. The most common symptoms include hematuria, dysuria, frequent urination, back pain, and pelvic pain (Centers for Disease Control and Prevention, 2023; Mayo Clinic, 2024).

Bladder cancer is broadly categorized into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). MIBC is further classified into locally advanced and metastatic bladder cancer (Cancer Research UK, 2022, 2023a). NMIBC has been categorized into risk groups by the European Association of Urology (EAU) 2021 as low, intermediate, high, and very high risk (Gontero et al., 2024). Genetic mutations in the FGFR 2, FGFR 3, and HER 2 genes are associated with an increased risk of developing bladder cancer. Based on these genetic mutations, physicians determine patient treatment and prognosis (Hayashi et al., 2020).

In the 8MM, the diagnosed incident cases of bladder cancer are expected to increase from 279,419 cases in 2023 to 341,879 cases in 2033, at an annual growth rate (AGR) of 2.24%. In 2033, the US will have the highest number of diagnosed incident cases of bladder cancer in the 8MM, with 98,184 diagnosed incident cases, whereas France will have the fewest diagnosed incident cases with 18,425 cases. In the 8MM, the five-year diagnosed prevalent cases of bladder cancer are expected to increase from 987,497 cases in 2023 to 1,202,635 cases in 2033, at an AGR of 2.18%. GlobalData epidemiologists attribute the increase in the diagnosed incident cases and five-year diagnosed prevalent cases to a certain extent with the moderately rising trend in the incidence rates in the 8MM, combined with underlying demographic changes in the respective markets.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for bladder cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
• The report includes a 10-year epidemiology forecast for the diagnosed incident cases of bladder cancer and five-year diagnosed prevalent cases of bladder cancer. The diagnosed incident cases of bladder cancer are segmented by age (18 years and older) and sex.
• The diagnosed incident cases of bladder cancer are further segmented by stage at diagnosis using the American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis (TNM) staging (Stage 0a, 0is, I, II, IIIA, IIIB, IVA, and IVB), and by tumor "T" stage at diagnosis (stage Ta, Tis, T1, T2a, T2b, T3a, T3b, T4a, and T4b). They are also segmented by broad classification into NMIBC, MIBC, locally advanced, and metastatic, and by mutations and biomarkers (PD-L1 positive, FGFR 2 mutations, FGFR 3 mutations, HER2 mutations, circulating DNA [ctDNA] positive in MIBC, patients with high tumor mutational burden of more than 10 mutations per megabase, and homologous recombination [HR] deficient).
• Additionally, the diagnosed incident cases of stage Ta bladder cancer are segmented by grade (low-grade and high-grade), and the diagnosed incident cases of NMIBC are segmented by risk group (low, intermediate, high, and very high). The five-year diagnosed prevalent cases of bladder cancer are segmented by stage (Ta, Tis, T1, T2, T3, T4, and all stages), broad classification (NMIBC, MIBC, locally advanced, and metastatic), relapse or recurrence (NMIBC to MIBC, NMIBC to distant metastasis or T4 MIBC, T2 MIBC to locally advanced or T3, and T2 and T3 MIBC to distant metastasis or T4 MIBC), and by treatment (NMIBC cases with Bacillus Calmette-Guerin [BCG] failure including refractory, intolerant, unresponsive, and relapsing; metastatic bladder cancer cases that are cisplatin ineligible; and MIBC cases that are cisplatin ineligible).
• This epidemiology forecast for bladder cancer is supported by data obtained from country-specific oncology databases, peer-reviewed articles, and population-based studies.
• The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed incident and diagnosed prevalent cases of bladder cancer across these markets.

Reasons to Buy

The Bladder Cancer epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global Bladder Cancer market.
• Quantify patient populations in the global Bladder Cancer market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Bladder Cancer therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData

1 Bladder Cancer: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities.
• 2.3 Global and historical trends
• 2.4 8MM forecast methodology.
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods.
  • 2.4.3 Forecast assumptions and methods: diagnosed incident cases of bladder cancer - 8MM
  • 2.4.4 Forecast assumptions and methods: diagnosed incident cases by stage at diagnosis using the AJCC TNM staging.
  • 2.4.5 Forecast assumptions and methods: diagnosed incident cases by tumor "T" stage at diagnosis.
  • 2.4.6 Forecast assumptions and methods: diagnosed incident cases of stage Ta bladder cancer by grade
  • 2.4.7 Forecast assumptions and methods: diagnosed incident cases and diagnosed prevalent cases of bladder cancer by broad classification
  • 2.4.8 Forecast assumptions and methods: diagnosed incident cases of NMIBC by risk group
  • 2.4.9 Forecast assumptions and methods: diagnosed incident cases of bladder cancer by mutations and biomarkers.
  • 2.4.10 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer.
  • 2.4.11 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by tumor stage.
  • 2.4.12 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence.
  • 2.4.13 Forecast assumptions and methods: five-year diagnosed prevalent cases of bladder cancer by treatment.
• 2.5 Epidemiological forecast for bladder cancer (2023-33)
  • 2.5.1 Diagnosed incident cases of bladder cancer.
  • 2.5.2 Age-specific diagnosed incident cases of bladder cancer
  • 2.5.3 Sex-specific diagnosed incident cases of bladder cancer
  • 2.5.4 Diagnosed incident cases of bladder cancer by stage at diagnosis using the AJCC TNM staging.
  • 2.5.5 Diagnosed incident cases of bladder cancer by tumor "T" stage at diagnosis.
  • 2.5.6 Diagnosed incident cases of stage Ta bladder cancer by grade.
  • 2.5.7 Diagnosed incident cases of bladder cancer by broad classification.
  • 2.5.8 Diagnosed incident cases of NMIBC by risk group.
  • 2.5.9 Diagnosed incident cases of bladder cancer by mutations and biomarkers.
  • 2.5.10 Five-year diagnosed prevalent cases of bladder cancer
  • 2.5.11 Five-year diagnosed prevalent cases of bladder cancer by tumor stage
  • 2.5.12 Five-year diagnosed prevalent cases of bladder cancer by broad classification
  • 2.5.13 Five-year diagnosed prevalent cases of bladder cancer by relapse or recurrence
  • 2.5.14 Five-year diagnosed prevalent cases of bladder cancer by treatment
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact.
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us